Caprock Group LLC Purchases Shares of 49,305 Novo Nordisk A/S $NVO

Caprock Group LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 49,305 shares of the company’s stock, valued at approximately $2,784,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jennison Associates LLC lifted its stake in Novo Nordisk A/S by 0.3% in the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after purchasing an additional 63,341 shares during the last quarter. Loomis Sayles & Co. L P increased its holdings in shares of Novo Nordisk A/S by 1.5% in the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock worth $867,998,000 after buying an additional 187,789 shares during the period. Folketrygdfondet lifted its stake in shares of Novo Nordisk A/S by 1.2% in the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock valued at $566,659,000 after acquiring an additional 117,370 shares during the last quarter. Sustainable Growth Advisers LP lifted its stake in shares of Novo Nordisk A/S by 11.7% in the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after acquiring an additional 649,390 shares during the last quarter. Finally, State Street Corp boosted its holdings in Novo Nordisk A/S by 0.8% during the 2nd quarter. State Street Corp now owns 6,047,683 shares of the company’s stock valued at $418,231,000 after acquiring an additional 47,430 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. HSBC reiterated a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Citigroup started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating for the company. CICC Research initiated coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target for the company. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus target price of $56.07.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo is planning to roll out Wegovy in vial format (and other device presentations), which could broaden distribution channels, improve dosing flexibility and help meet demand amid intense competition. Novo Nordisk plans Wegovy vials amid obesity-drug competition
• Positive Sentiment: CEO Mike Doustdar highlighted a potential ~15 million-patient Medicare opportunity once obesity treatments gain coverage — a large TAM that supports long-term revenue upside if access improves. Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
• Positive Sentiment: A study found many Wegovy pill users are new to GLP‑1 therapies, suggesting the product is expanding the market rather than only cannibalizing existing diabetes/weight-loss patients. That supports growth potential if retention and outcomes hold. Many users of Novo Nordisk Wegovy pill new to GLP-1s – study
• Neutral Sentiment: Coverage on how Novo is expanding its global healthcare reach highlights strategic initiatives and portfolio breadth, but offers limited immediate impact to near-term earnings. How Is Novo Nordisk (NYSE:NVO) Expanding Its Global Healthcare Reach?
• Neutral Sentiment: Coverage comparing Eli Lilly and Novo Nordisk notes intense competition in the weight‑loss market; investors should watch share shifts but the piece is a market-context update rather than firm-specific news. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here’s What Investors Need to Know.
• Neutral Sentiment: Company disclosure of insider trading by board members/executives was published; routine regulatory reporting that bears watching only if it signals large directional bets. Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
• Negative Sentiment: Regulatory pressure is mounting: the FDA flagged a TV ad for the Wegovy pill as misleading and broader reporting highlights potential FDA warnings and lawsuits — these raise reputational, marketing and legal risk that could dent demand or increase costs. Novo’s TV ad for Wegovy pill was misleading, FDA says FDA Wegovy Warning And Lawsuits Test Novo Nordisk Valuation Story
• Negative Sentiment: Analysts are turning cautious: Deutsche Bank cut its price target ~16% citing revenue headwinds and risks, and Zacks downgraded Novo to a “strong sell” — analyst actions can pressure sentiment and share price near term. Novo Nordisk target cut by Deutsche Bank despite long-term optimism Zacks Research downgrade

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $48.91 on Friday. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The stock has a market capitalization of $218.39 billion, a P/E ratio of 14.10 and a beta of 0.67. The company’s 50-day moving average is $53.71 and its 200 day moving average is $53.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.